Research programme: JAK2 inhibitors - Eli Lilly and Company
Alternative Names: JAK2 inhibitors - SGX PharmaceuticalsLatest Information Update: 04 Nov 2017
At a glance
- Originator SGX Pharmaceuticals
- Developer Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Janus kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myeloproliferative disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Myeloproliferative disorders in USA (PO)
- 24 Oct 2008 Pharmacodynamics, pharmacokinetics and safety data from preclinical trials in Myeloproliferative disorders presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
- 19 Feb 2007 Preclinical trials in Myeloproliferative disorders in USA (PO)